Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amcenestrant pharmacokinetics in hepatic impairment
NCT05126329Phase 1Terminated
- Sponsor
- Sanofi
- Start
- Nov 2021
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of amcenestrant (3 arms), sponsored by Sanofi. Primary endpoints: Maximum plasma concentration observed and Area under the plasma concentration curve. Started Nov 2021; status: terminated.
02
Drugs
amcenestrant
Beyond the preview
Go deeper on NCT05126329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05126329.